Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...
Netflix flexes documentary muscle with eight projects in the running for an Oscar, but National Geo, others have strong ...
Parent Project Muscular Dystrophy, a nonprofit that seeks to accelerate research ... potential treatments and that these ...
EBR Systems is among ASX healthcare stocks with upcoming catalysts, expecting feedback on a FDA substantive review expected ...
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...
Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...
Brian Skorney, an analyst from Robert W. Baird, maintained the Buy rating on RegenXBio (RGNX – Research Report). The associated price ...
Harbor Capital Advisors Inc. increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) by 48.5% during the third quarter, HoldingsChannel reports. The fund owned 36,082 shares of ...
Edgewise Therapeutics, Inc. ( (EWTX) ) has released its Q3 earnings. Here is a breakdown of the information Edgewise Therapeutics, Inc.
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback